Science & Technology

Powering Vision with Science, Together

Science Over Cancer

Vivacitas Oncology, Inc. is developing next-generation technology coupled with proprietary synthesis methods to serve patients with particularly challenging prognoses.

Our lead development candidate (AR-67) is a novel lipophilic compound demonstrating high blood stability, targeting improved efficacy and tolerability.

Other development candidates include Rubitecan (Orathecin), a 2nd generation, semi-synthetic Camptothecin with potential for oral delivery.

Our team of top scientists is breaking new ground on cancer treatment options for patients through scientific discovery.

  • Next-Generation Camptothecin to improve efficacy and tolerability
  • Well understood target and mechanism of action
  • Proprietary synthesis
  • Unique, Patient-Focused Innovation
  • Orphan Drug Designation for Glioblastoma Multiforme
Learn More

We are pioneering new synthesis methods to give patients and their families new alternatives in the fight against aggressive cancers

  • Proprietary Synthesis Method
  • Results Backed by Scientific Data
  • Unique lipophilic molecular design

Please look at what is best placed in our science, which is the unique design of our lipophilic molecule, and what is best in our technology, which is the proprietary synthesis method

Learn More
AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.
Dr. Gerard Blobe, MD, PhD.Duke University School of Medicine.
AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.
Dr. Jai Grewal, MD.NSPC Brain and Spine Surgery, NY

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org